GGrantIndex
← Leaderboards

Sara Michelle Thomasy

University Of California At Davis

$8,532,621
Attributed
$18,578,231
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY201125
$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,578,231 · 10

By mechanism

U24$7,664,347 · 1
R01$5,971,404 · 4
U01$2,175,000 · 1
T32$1,544,695 · 1
K08$879,120 · 1
P30$343,665 · 2

Most similar at University Of California At Davis

Same institution · by research overlap

Others in their field

Top investigators on “Animal Model

Research focus

Animal ModelBlindnessAnimalsAffectCellsNonhuman PrimateResponseCharacteristicsSignal TransductionVisionEfficacy TestingMacaca MulattaRetinaDisease ProgressionProteinsGeneticElectroretinographyGenesNovel TherapeuticsPhenotypeCommunitiesCorneaExtracellular MatrixMutation

Grant awards (39)

Advancing novel therapies for optic neuropathy with a nonhuman primate model$715,063
R01 · FY2025 · EY · contact PI
Unlocking Corneal Endothelial Regeneration: Novel Therapeutic Strategies for Fuchs' Endothelial Corneal Dystrophy$709,979
R01 · FY2025 · EY
Modulating Ferroptosis in Fuchs Endothelial Corneal Dystrophy$588,731
R01 · FY2025 · EY
Comparative Medical Science Training Program$373,095
T32 · FY2025 · OD · contact PI
Large Animal Core$106,099
P30 · FY2025 · EY · contact PI
Unlocking Corneal Endothelial Regeneration: Novel Therapeutic Strategies for Fuchs' Endothelial Corneal Dystrophy$732,045
R01 · FY2024 · EY
Advancing novel therapies for optic neuropathy with a nonhuman primate model$699,749
R01 · FY2024 · EY · contact PI
Comparative Medical Science Training Program$592,917
T32 · FY2024 · OD · contact PI
Large Animal Core$106,099
P30 · FY2024 · EY · contact PI
Advancing novel therapies for optic neuropathy with a nonhuman primate model$39,755
R01 · FY2024 · EY · contact PI
Advancing novel therapies for optic neuropathy with a nonhuman primate model$693,281
R01 · FY2023 · EY · contact PI
Comparative Medical Science Training Program$578,683
T32 · FY2023 · OD · contact PI
Mechanotransduction in corneal disorders$389,700
R01 · FY2023 · EY · contact PI
Novel model systems for the study of cone disorders and other heritable retinal diseases$157,562
U24 · FY2023 · EY
Large Animal Core$131,467
P30 · FY2023 · EY · contact PI
Mechanotransduction in corneal disorders$70,060
R01 · FY2023 · EY · contact PI
Diversity Supplement: Advancing novel therapies for optic neuropathy with a nonhuman primate model$55,449
R01 · FY2023 · EY · contact PI
Novel model systems for the study of cone disorders and other heritable retinal diseases$1,294,245
U24 · FY2022 · EY
Mechanotransduction in corneal disorders$378,009
R01 · FY2022 · EY · contact PI
Mechanotransduction in corneal disorders$117,624
R01 · FY2022 · EY
Novel model systems for the study of cone disorders and other heritable retinal diseases$1,406,263
U24 · FY2021 · EY
Mechanotransduction in corneal disorders$378,009
R01 · FY2021 · EY
Novel model systems for the study of cone disorders and other heritable retinal diseases$150,000
U24 · FY2021 · EY
Novel model systems for the study of cone disorders and other heritable retinal diseases$1,404,821
U24 · FY2020 · EY
Respiratory and Ocular Toxicity of Inhaled Nanomaterials$435,000
U01 · FY2020 · ES
Mechanotransduction in corneal disorders$403,950
R01 · FY2020 · EY
Novel Model Systems for the Study of Cone Disorders and Other Heritable Retinal Diseases$393,484
U24 · FY2020 · EY
Novel model systems for the study of cone disorders and other heritable retinal diseases$1,291,677
U24 · FY2019 · EY
Respiratory and Ocular Toxicity of Inhaled Nanomaterials$435,000
U01 · FY2019 · ES
Novel model systems for the study of cone disorders and other heritable retinal diseases$227,267
U24 · FY2019 · EY
Novel model systems for the study of cone disorders and other heritable retinal diseases$1,339,028
U24 · FY2018 · EY
Respiratory and Ocular Toxicity of Inhaled Nanomaterials$435,000
U01 · FY2018 · ES
Respiratory and Ocular Toxicity of Inhaled Nanomaterials$435,000
U01 · FY2017 · ES
Respiratory and Ocular Toxicity of Inhaled Nanomaterials$435,000
U01 · FY2016 · ES
Engineering the Corneal Wound Bed to Promote Healing$175,824
K08 · FY2015 · EY · contact PI
Engineering the Corneal Wound Bed to Promote Healing$175,824
K08 · FY2014 · EY · contact PI
Engineering the Corneal Wound Bed to Promote Healing$175,824
K08 · FY2013 · EY · contact PI
Engineering the Corneal Wound Bed to Promote Healing$175,824
K08 · FY2012 · EY · contact PI
Engineering the Corneal Wound Bed to Promote Healing$175,824
K08 · FY2011 · EY · contact PI